Shares in AstraZeneca (AZN) spiked almost 5% in after-market trading amid a report that early-stage human trial data on the drugmaker’s coronavirus vaccine candidate will be disclosed on July 20.The stock rose to $60.60 in Wednesday’s extended trading after earlier jumping 7%. Data results from the Phase 1 trial of the potential coronavirus vaccine, also kno […]

Read More